While GFAP alone reflects astrocytic activation and neuroinflammation, which are common across various neurodegenerative diseases, its diagnostic utility is significantly enhanced when used alongside with established Alzheimer’s disease biomarkers. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.